Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
February 26, 2026
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone. I'm Corey, and I'll be the conference operator for today. I'd like to welcome all of you to Cronos Group's 2025 fourth quarter and full-year earnings conference call. If you'd like to ask a question during the session, you'll need to press *11 on your telephone. After that, you will hear an automated message advising you your hand is raised. To withdraw your question, please press *11 again. Please be advised that today's conference is being recorded. At this time, I would like to turn the call over to Harrison Aaron, Senior Director, Investor Relations and Corporate Development. Please go ahead.
Harrison Aaron
executiveThanks, Corey, and I appreciate everyone being here today as we go through Cronos's financial and business results for the fourth quarter and the full year of 2025. With me on the call are our Chairman, President, and CEO, Mike Gorenstein, along with our CFO, Anna Shlimak. This morning Cronos put out a news release with our financial results, and it's been filed on our EDGAR and SEDAR profiles. You'll also find this information and the prepared remarks on our website in the Investor Relations section. Before handing things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, which carry risks and uncertainties that could make actual results differ materially from what those forward-looking statements project. The factors that could cause actual results to differ materially from expectations are set out in detail in our earnings materials and in our SEC filings available on our website, and any forward-looking statements made during this call are qualified in their entirety by those documents. Details on non-GAAP financial measures, including reconciliations to U.S. GAAP, are likewise in the earnings materials posted on our website.
Harrison Aaron
executiveAnd finally, throughout this conference call we'll be sharing statements about market share information, and unless otherwise stated, all of that market share data comes from Hifyre. We'll now deliver prepared remarks, and after that we'll transition to a question-and-answer session. So with that, I'll hand things over to the Chairman, President, and CEO of Cronos, Mike Gorenstein.
Mike Gorenstein
executiveThanks, Harrison. In 2025, Cronos had a record year, with net revenue up 25% organically, which highlights how our core business remains strong and the headway we're making on our strategic priorities. We hit record net revenue for both the fourth quarter and the full year, and we posted record full-year gross profit and adjusted EBITDA. Those results show robust consumer demand for our leading brands as well as the increasing contribution from Israel and our international platform. In Canada, we had record quarterly net revenue, rising 42% year-over-year, driven in large part by flower, vapes, and edibles. Spinach remains a standout in the Canadian market and ranks as the second most popular brand nationally. On the vapes side, Spinach put up a stellar performance this quarter. In December, Spinach moved into the number two overall vape brand spot in Canada, up from the number four share position in the first quarter of 2025. In the vape cartridges subcategory, Spinach took the number one market share in the fourth quarter, with Cherry Crush and Blueberry Dynamite as the two best-selling vape cartridges across the country. This vape performance demonstrates our capacity to use extensive R&D and consumer insights work to build market-leading products that connect strongly with consumers.
Mike Gorenstein
executiveWe aim to keep that momentum going, and late in the fourth quarter we introduced Spinach Puffers, our latest addition to the all-in-one vape device segment. Puffers delivers bold flavors of premium liquid diamond infused cannabis in a modern, palm-style design, featuring a dual ceramic coil for maximum flavor and smooth draws, along with a uniquely satisfying tactile grip. The initial rollout of Puffers was in select Canadian markets, and distribution will expand to additional Canadian provinces in early 2026. Innovation remains among our greatest competitive strengths, and Puffers stands as yet another illustration of how we elevate the bar on product quality, design, and flavor. As we keep building consumer loyalty, our focus stays on making products that look, feel, and taste great, delivering the exceptional experiences that define the Spinach brand. On edibles, SOURZ kept up strong growth while holding category leadership, with market share nearing 22% for the quarter. That growth came from Fully Blasted multipacks, which, even though they only launched in mid-2025, accounted for four of the top 10 selling edible SKUs in Canada during the fourth quarter, including the number one edible SKU nationwide, reinforcing Spinach's leadership position in edibles and showing the success of our innovation pipeline.
Mike Gorenstein
executiveDuring the quarter, Spinach held onto the number four brand position in flower, though supply constraints kept growth potential in check. Now that the GrowCo expansion is finished and the added cultivation space is still being fine-tuned, we anticipate those supply constraints will let up in 2026. Moving to Lord Jones, the brand is still the leader in Canada's market for hash and live resin-infused pre-rolls, which underscores its strength in premium formats — the areas where quality and differentiation count the most. Earlier this month, Lord Jones made its debut in Israel with a collection of curated premium flower offerings that feature cold-cured, large buds, released through a series of limited-time drops — an important step toward widening the brand's presence. On the international side, PEACE NATURALS and Lit delivered yet another impressive quarter. In Israel, net revenue rose 52% year-over-year — the eighth consecutive quarter of record net revenue for Cronos in that market. PEACE NATURALS stayed the top-selling brand in the market, according to pharmacy data Cronos collected, and it keeps benefiting from strong brand equity, consistent product quality, and stellar commercial execution. Beyond Israel, PEACE NATURALS and Lit powered a strong quarter across our other international markets, with net revenue climbing 68% year-over-year, led by growth in Germany as shipment timing normalized and demand stayed strong.
Mike Gorenstein
executiveWe wrapped up the year with the December news that we signed a definitive agreement to purchase CanAdelaar, and we expect that deal to close during the first half of 2026. According to CanAdelaar management data, CanAdelaar is the biggest company operating in the Netherlands legal adult-use cannabis program, and it is the sole industrial-scale greenhouse cultivator in that program. Per the agreement, Cronos will buy CanAdelaar for upfront consideration of €57.5 million, or roughly $67.5 million, subject to certain adjustments, plus additional contingent consideration tied to half X CanAdelaar's normalized EBITDA in '26 and '27. The Netherlands has a rich cannabis heritage, and its coffee shops, which function as cannabis retailers, are known around the world for having played a foundational role in the evolution of the legal cannabis industry. The Dutch legal adult-use cannabis program was enacted in 2020 to create a closed, regulated cannabis supply chain across 10 participating municipalities, with the start-up phase beginning in the fourth quarter of 2023 and the program officially launching on April 7th, 2025. The program is set to run for four years from that date, and the Dutch government keeps the option to extend it by up to an additional 18 months. The program is well-designed and regulated to limit cannabis to responsible levels among adult consumers only, serving as a potential model for other countries.
Mike Gorenstein
executiveWe're dedicated to keeping the program going and to working with regulators, municipalities, and every stakeholder in the industry so that it succeeds over the long term. As part of this program, every one of the 72 cannabis retailers across the 10 participating municipalities must now obtain their cannabis products solely from one of 10 licensed producers, and CanAdelaar is among them. Counting those 72 cannabis retailers in the program, the Netherlands has 562 cannabis retailers in total, according to Dutch government data, which means the addressable market could grow substantially if the program is ultimately extended to more municipalities or rolled out nationwide. Expanding in Europe is a key priority for us, and if the deal closes, picking up a market leader in Europe's biggest adult-use cannabis market will let us further leverage our investment in borderless products at scale. Along with a highly attractive financial profile and the expectation of accretion from the transaction, we're excited to welcome CanAdelaar into the Cronos family and to build on the foundation the company has laid. Cronos has the strongest balance sheet in the industry, carrying no debt and $832 million in cash, cash equivalents, and short-term investments, which lets us keep investing in growth, innovation, and global expansion.
Mike Gorenstein
executiveAt this point, I'll hand things over to Anna so she can take you through the financial results for the fourth quarter and the full year.
Anna Shlimak
executiveThanks, Mike, and good morning, everyone. I'll now review our fourth quarter 2025 results. The company reported consolidated net revenue of $44.5 million, a 47% increase year-over-year. The net revenue increase was driven by higher cannabis flower sales in Israel, Canada, and other countries, and higher cannabis extract sales in the Canadian market. Gross profit and adjusted gross profit in the fourth quarter were $16.2 million, equating to a 36% margin, a 670 basis point improvement from the 30% adjusted gross margin in Q4 2024. The year-over-year margin improvement was driven by higher average sales prices due primarily to a mix shift to Israel and other countries, and higher sales volume. Adjusted gross margin declined from the levels realized in the first three quarters of 2025. This was driven by adverse production quality mix at GrowCo, as GrowCo dialed in the expansion, as well as an expense timing in Q4 as part of that ramp-up. For full-year 2025, adjusted gross margin of 43%, and we would view this as a reasonable margin level for the business. Operating expenses, excluding restructuring costs and impairments, were $22.5 million in the quarter, a modest year-over-year increase of $0.3 million. Adjusted EBITDA in the fourth quarter was $0.5 million, an improvement of $7.7 million year-over-year, driven by higher adjusted gross profit.
Anna Shlimak
executiveEven though we stayed positive, adjusted EBITDA came in below what was reported across the first three quarters of the year, because of gross margin pressures and the timing of expenses. We continue to feel confident about the operating leverage in the business as production stabilizes and scale efficiencies are realized. Moving to the balance sheet and cash flow statement, the company finished the quarter with $832 million in cash, cash equivalents, and short-term investments, which is up $8 million from Q3 2025, driven primarily by positive cash flow from operations before changes in working capital of $18 million and $3 million of proceeds from the sale of the Cronos Fermentation facility, partially offset by a $7 million working capital outflow, $4 million of share repurchases, and $2 million of CapEx spend. Beyond this cash balance, we hold $21 million of loans receivable and $8 million of other investments. To sum up, our fourth quarter jump in topline set a net revenue record, setting the stage for bottom-line growth in 2026. For full-year 2025, we achieved record net revenue, gross profit, and adjusted EBITDA, demonstrating continued improvement in our operating fundamentals as we execute against our business objectives. With that, I would like to hand it back to Mike for a brief comment before going into Q&A.
Mike Gorenstein
executiveThanks, Anna. To sum up, we achieved significant gains in both our operations and our financial performance during 2025, expanding net revenue organically at a rate of 25% compared with the prior year, and reinforcing our competitive standing in key markets and product categories. The context behind this organic growth relative to our peers matters. We achieved growth without making any acquisition, and beyond that, while the majority of our peers carry ATMs and have issued shares to finance their operations, our solid balance sheet and self-sustaining business have allowed us to run an active share repurchase program, which resulted in a declining share count throughout 2025. As we look toward 2026, our commitment to that share repurchase program remains. We will also stay opportunistic and disciplined as we assess M&A opportunities. CanAdelaar illustrates a transaction that lets us push forward with our borderless product strategy and build a strong foothold in an important market. Alongside new market opportunities, we will seek out strong brands and IP that we can bring into our portfolio. We see several drivers of continued momentum this year: the anticipated closing of the CanAdelaar transaction, greater production capacity after GrowCo's expansion, ongoing growth in our branded products, and our expanding presence in international markets.
Mike Gorenstein
executiveOur priority is still to generate durable revenue growth with appealing gross margins, and to keep cost control rigorous as we keep expanding Cronos around the world and set the company up for success over the long term. Thank you — we will now take questions from the call.
Operator
operatorThanks a lot. We're going to move into a question-and-answer session now. Just a reminder: if you'd like to ask something, press *11 on your phone and then wait until your name gets called. If you want to take your question back, just hit *11 once more. Please hold on while we put together the Q&A roster. Our first question is from Bill Kirk at Roth Capital Partners. Bill, your line is open.
Bill Kirk
analystMorning, everyone. I was hoping to spend a little time on how product gets allocated from the new GrowCo capacity. How are the decisions made about where that product goes? How did it end up being allocated in 4Q? Are there considerations such as permit timing or anything along those lines that could shift future allocation away from what we see in 4Q?
Mike Gorenstein
executiveThanks, Bill. In the past, I think our approach has really been about figuring out how to operate from a scarcity standpoint and distribute what we had, so we were balancing two things: making sure we maintained a certain demand level in markets while also concentrating on margin. Now, with additional supply coming on and quality supply expected to hold steady at the levels we've had historically, I think we can begin placing more product into Canada and also move somewhat more aggressively on scaling in Europe. In Q4, I think you saw us working to bring out a lot of the new product. We may not have had the same typical fills as usual, but beginning this year that ought to return to something more in line with what we saw previously, except that Canada will have more product available than it did historically.
Bill Kirk
analystUnderstood. So, Anna, you mentioned that gross margins going forward would be comparable to full-year 2025 levels. What specifically drives the gross margin improvement relative to what you reported in 4Q? Is price the bigger factor? Is it improved mix? Or is it cost reductions? And then, given the higher sales and scale from GrowCo, why is it that gross margin can't exceed 2025? Sure.
Anna Shlimak
executiveThanks, Bill. So in Q4, we ran into a couple of challenges. We saw some production quality mix tied to expansion from the GrowCo scale-up, plus certain one-time costs that ran through COGS because of the ramp-up. Those are the headwinds that hit Q4, and we don't anticipate them carrying into future periods. That's the reason we think a 43% margin range for the full year is a sensible expectation for the business. Look, I do see room for margin expansion down the road, but we've got to stay balanced, right? Margin compression in Europe is also possible. We just don't know at this point, but we feel good about that full-year 2025 run rate as we move ahead.
Bill Kirk
analystAlright, thanks.
Operator
operatorMuch appreciated. The next person to ask something is Kendrick Tyghe from Canaccord Genuity Capital Markets. Kenric, we're ready for you.
Kendrick Tai
analystThanks, and good morning. Let me just jump in quickly with a follow-up question about gross margin. Anna, you're mentioning roughly the same levels for full-year '25. Just to clarify, do those expectations include the closing of CanAdelaar, or could there be additional upside, and is that maybe what you were hinting at when you said there might be some further expansion as the year goes on? How should we think about how this could evolve, following up on what you said earlier?
Anna Shlimak
executiveAbsolutely. Those remarks applied only to Cronos as a standalone company, leaving CanAdelaar out of the picture. That business is profitable too, with gross margins that are quite attractive. We could see a bit of margin expansion come from it. I'm really talking about our own business on a standalone basis — that 43% going forward. Great.
Kendrick Tai
analystThanks for clearing that up. Now, on the timing within the quarter, if I may. Regarding revenue and the beat — you highlighted roughly 68% growth internationally, and I believe it was 52% growth in Israel. Of the revenue beat this quarter, how much came from a timing shift versus what you'd call pure Q4?
Anna Shlimak
executiveAbsolutely. For the international markets beyond Israel, a few things shifted in timing from Q3 into Q4. Some shipping schedules slid into Q4 as well, but beyond that, our business is expanding, and you should expect us to show that going forward in all of our markets.
Kendrick Tai
analystThanks. Sorry — perhaps just a single last quick question. On CapEx, are there any key initiatives we ought to keep in mind for this year? Given the Q4 spend and what we now understand about your needs or build in 2026, was it reasonable to expect we'd be looking at under $10 million for the year?
Anna Shlimak
executiveThat seems correct to me. Those strike me as suitable levels for us moving ahead.
Kendrick Tai
analystPerfect, thanks. I’ll rejoin the queue.
Operator
operatorMuch appreciated. Moving on, the next person to ask something is Ryan Neal from TD Cowen. Ryan, go ahead—you're live.
Ryan Neal
analystGood morning, everyone. Ryan here, filling in for Derek. I wanted to jump right into the domestic market. Clearly, Canada came in above 40% year-over-year. Could you walk us through a few of the factors behind that, and in particular, I know you noted in Q3 that flower sales were still somewhat softer because of domestic supply constraints?
Mike Gorenstein
executiveMy view is that added supply is among the largest factors at play here, and I expect that will keep flowing through. Up until this quarter, our real challenge was figuring out how to divide up the scarce product we possessed, and now that more product is beginning to come online, I believe that lets us serve the demand that already exists in the markets where we operate.
Ryan Neal
analystThanks. So you clearly have quite a substantial capital base. What I'd like to know is how you're looking at the pipeline of potential opportunities right now, and how you might put some of that capital to work going forward.
Mike Gorenstein
executiveAbsolutely. First, I believe keeping our commitment to the buyback matters a great deal for us. Internationally, there is plenty we are examining. Whether that fits into the category of a new market and whether there is anything we must do to extend our platform, but also whether there are new products, new brands we could place onto our current platform and then gain the advantage of bringing those into new markets — I think that's part of it. We will remain disciplined and stay opportunistic, and as 2025 has shown you, whenever opportunities arise, we will definitely act on them.
Ryan Neal
analystThanks. I’ll add just one more question here. I’m interested in some of the innovation you’re working on. I know on the previous call you mentioned several launches. How are those performing, and which categories are showing the greatest strength?
Mike Gorenstein
executiveOne thing people don't always notice right away — and it's tougher to quantify — is genetics, which matters a great deal to us. We've done a lot with breeding over the years, and I think each year you can see the wins that result from it, and we have some genuinely intriguing genetics projects underway. We're very excited about that. Continuing to innovate in edibles is really important to us, keeping SOURZ fresh. Possibly the most exciting item for this quarter — and you'll see it reflected in the data in Q1 — is in vapes, Puffers. It's our all-in-one. We've devoted a lot of time and effort to ensuring this will be a major driver for us, and I think the early success is already visible. Puffers is the thing I believe all of us are most enthusiastic about at the moment.
Ryan Neal
analystThanks a lot, everyone.
Operator
operatorMuch appreciated. We now take a question from Pablo Zuanic, who is with Zuanic & Associates. Pablo, the floor is yours.
Pablo Zuanic
analystMuch appreciated, and hello everybody. Mike, given the consolidation happening in Germany—with High Tide, Remexian, OGI, and Sanity involved—could you walk us through the reasoning for prioritizing Holland ahead of Germany, particularly since that market is consolidating and a number of distributors remain up for grabs? Many thanks.
Mike Gorenstein
executiveSure. When I look at Germany, what stands out first is that regulatory uncertainty remains, and there's some movement underway, and we anticipate gaining clarity over the next few months. Also, if you consider license availability, distribution, and the chance to enter that market, there's ample opportunity to get in, with many options available there, and from a business model standpoint, I think it can be tricky, because some of the distributors you might look at acquiring, well, they carry many brands on the platform, there's a great deal of different distribution, and I think you can't be sure whether you're picking up a business where you'll still have that distribution business, since they're distributing your competitors' products. It's something we keep evaluating, thinking about the smartest way we could deepen our presence in that market. We felt the Netherlands was much more on strategy. It's a market where, absent making an acquisition, we would have no way to get in, because it's closed as far as import-export. It has its own supply base, its own brands, and we feel like it's not a step toward getting toward adult use and building a brand, it is moving directly into the adult-use market in a place where you've had a 50-year history of adult-use sales, and we think that gets the most brand leverage for any market across Europe just given the kind of culture and history around the Netherlands coffee shops.
Mike Gorenstein
executiveIn our view, it was simply very logical, and for us it represented a truly one-of-a-kind chance.
Pablo Zuanic
analystThanks. I’ll just ask one quick follow-up. In markets such as Australia, we have observed operators and distributors acquiring control of downstream assets, whether clinics or even online pharmacies. Apparently we are starting to see that in Germany, and it is occurring in the UK. Curaleaf owns a clinic there as well as an online pharmacy. How do you view downstream opportunities over the medium to longer term, or is that an area you would rather not be involved in? Thanks.
Mike Gorenstein
executiveThank you. That's an excellent question. When it comes to acquisitions and capital spending, we tend to think very long term, and I believe it can depend on the specific market, but I'm always asking myself where I expect that market to ultimately land. If it's a business that looks more temporary, or if we're concerned that regulations might shift it, that's a case where we'd rather be a customer than an owner of the asset. If I believe it will be locked in for a longer stretch and we're able to model it out and see a long-term payback from owning rather than being a customer, then that's something we'd consider. I think it really is market specific, but I do come back to the experience we had early on in Canada. If it's a market where we expect it to go adult use, or if it's a market where we think regulations can change, and what that funnel looks like, that's something where we'd rather just spend money to help with marketing and demand instead of being, in a sense, an owner of that part of the funnel.
Pablo Zuanic
analystThanks. If I could squeeze in one final question. I realize this reaches back a while, but what did you learn from that option you picked up in PharmaCann? As I recall, you held an option to purchase a stake in that business, and I know that was some time ago. What takeaways did the company draw from it, and how does that lesson shape your thinking now that the U.S. is starting to reschedule? Thanks. That's all. Sorry,
Mike Gorenstein
executiveMy line dropped for a moment there. I caught the lessons part, so could you go over what came after that once more? Sorry about that.
Pablo Zuanic
analystLet me restate that. Actually, looking back, my understanding is that Cronos held an option to buy a stake in PharmaCann in the U.S., correct? That business hasn't performed too well. What did Cronos take away from that experience, and how does it shape your view of upcoming opportunities in the U.S. as that country reschedules cannabis? Thank you.
Mike Gorenstein
executiveThanks. No, that's a really good question. I think there are two specific points I'd highlight. First, when we made that move, it was somewhat of a hedge. As you may remember, the timing coincided with the buzz surrounding the STATES Act. It was approximately 10% on the option, and one reason was that we wanted to ensure distribution was locked in should regulations shift. Part of that is that it remains important that we didn't take a bigger stake and that we were being, I'd say, somewhat more disciplined and measured. I think also, and a larger factor, is that you truly can't get ahead of regulations. What we've observed in this sector is that whenever you attempt to be aggressive and get ahead of regulations, it typically doesn't pan out. Particularly in the U.S., I think attempting to get creative with structures doesn't always play to your benefit, and ensuring you have routes to control and ways to operationally pivot when circumstances change is quite important. The U.S. is really the market where I believe those lessons will be most applicable, given the federal illegality, but the size of the business despite that.
Mike Gorenstein
executiveEven so, I view it as a highly significant market—one we keep watching and look for alternative routes into. But my sense is that unless you truly get the chance to enter, run operations there, and hold direct ownership, it makes more sense simply to keep growing the portfolio and accumulating strength beyond the U.S.
Pablo Zuanic
analystYeah, okay — thanks.
Operator
operatorThanks a lot. That brings the Q&A portion of the Cronos Group call to a close. Many thanks, and you're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 133,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 133,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.